Sphera Funds Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.7M | Buy |
219,987
+180,170
| +452% | +$12.9M | 2.44% | 10 |
|
|
2026
Q1 | $2.62M | Sell |
39,817
-51,900
| -57% | -$3.3M | 0.42% | 72 |
|
|
2025
Q4 | $5.83M | Sell |
91,717
-69,800
| -43% | -$4.34M | 1.13% | 36 |
|
|
2025
Q3 | $8.88M | Sell |
161,517
-165,201
| -51% | -$6.81M | 1.87% | 12 |
|
|
2025
Q2 | $10.8M | Buy |
326,718
+181,757
| +125% | +$6.32M | 2.53% | 6 |
|
|
2025
Q1 | $5.83M | Sell |
144,961
-8,060
| -5% | -$370K | 1.34% | 20 |
|
|
2024
Q4 | $7.2M | Sell |
153,021
-72,000
| -32% | -$3.74M | 1.3% | 23 |
|
|
2024
Q3 | $11.9M | Sell |
225,021
-159,903
| -42% | -$8.91M | 1.89% | 14 |
|
|
2024
Q2 | $20.9M | Buy |
384,924
+103,253
| +37% | +$6.23M | 2.84% | 5 |
|
|
2024
Q1 | $19.7M | Buy |
281,671
+57,851
| +26% | +$4.47M | 2.77% | 6 |
|
|
2023
Q4 | $18.7M | Sell |
223,820
-10,113
| -4% | -$366K | 3.01% | 4 |
|
|
2023
Q3 | $6.89M | Buy |
+233,933
| New | +$7.79M | 1.26% | 23 |
|
|
2020
Q1 | – | Sell |
-268,747
| Closed | -$2.85M | – | 85 |
|
|
2019
Q4 | $2.85M | Buy |
+268,747
| New | +$2.76M | 0.24% | 67 |
|
|
2018
Q1 | – | Sell |
-210,000
| Closed | -$1.71M | – | 120 |
|
|
2017
Q4 | $1.71M | Sell |
210,000
-17,990
| -8% | -$204K | 0.2% | 103 |
|
|
2017
Q3 | $3.31M | Buy |
227,990
+10,000
| +5% | +$137K | 0.47% | 57 |
|
|
2017
Q2 | $2.64M | Buy |
217,990
+65,790
| +43% | +$914K | 0.45% | 70 |
|
|
2017
Q1 | $1.96M | Buy |
+152,200
| New | +$1.78M | 0.38% | 73 |
|
|
2016
Q3 | – | Sell |
-32,069
| Closed | -$304K | – | 113 |
|
|
2016
Q2 | $304K | Sell |
32,069
-309,875
| -91% | -$2.54M | 0.08% | 87 |
|
|
2016
Q1 | $2.41M | Buy |
+341,944
| New | +$2.5M | 0.52% | 38 |
|
|
2015
Q4 | – | Sell |
-372,250
| Closed | -$2.49M | – | 121 |
|
|
2015
Q3 | $2.49M | Sell |
372,250
-50,000
| -12% | -$341K | 0.32% | 77 |
|
|
2015
Q2 | $2.84M | Buy |
+422,250
| New | +$2.77M | 0.28% | 97 |
|
|
2015
Q1 | – | Sell |
-493,212
| Closed | -$3.95M | – | 150 |
|
|
2014
Q4 | $3.95M | Buy |
493,212
+130,000
| +36% | +$558K | 0.67% | 45 |
|
|
2014
Q3 | $1.28M | Buy |
363,212
+298,112
| +458% | +$1.25M | 0.16% | 105 |
|
|
2014
Q2 | $311K | Sell |
65,100
-64,900
| -50% | -$396K | 0.08% | 91 |
|
|
2014
Q1 | $1.24M | Sell |
130,000
-37,000
| -22% | -$335K | 0.28% | 79 |
|
|
2013
Q4 | $1.09M | Buy |
+167,000
| New | +$1.1M | 0.3% | 75 |
|
Other funds holding CYTK
ACA
Sphera Funds Management's CYTK Position: Q2 2026 in Review
Sphera Funds Management increased its Cytokinetics (CYTK) stake by 452% in Q2 2026, buying an estimated $12.9M and bringing the position to 219,987 shares worth $18.7M. The position accounts for 2.44% of the portfolio, ranked #10.
Sphera Funds Management first reported a position in CYTK in Q4 2013 and has held it in 26 quarters since. The position peaked at $20.9M in Q2 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Sphera Funds Management held 219,987 shares of Cytokinetics worth $18.7M as of Q2 2026.
- Sphera Funds Management bought 180,170 Cytokinetics shares in Q2 2026, an estimated $12.9M.
- Cytokinetics made up 2.44% of Sphera Funds Management's portfolio in Q2 2026, its #10 holding.
- Sphera Funds Management first reported a position in Cytokinetics in Q4 2013 and has held it in 26 quarters since.
- Sphera Funds Management's Cytokinetics position peaked at $20.9M in Q2 2024.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.